The ACR applauds the FTC’s recent ban on most noncompete agreements. The ruling is a step in the right direction toward a more competitive market for healthcare workers and their services.
Commercial Payers Update Reimbursement for Underwater Infliximab Biosimilars
Three commercial health insurance payers have increased reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
Rheumatology’s Systems-Based Thinking Plays Well on Capitol Hill
One of the great joys of rheumatology is that it prioritizes systems-based thinking. Whether integrating data from radiographic imaging or piecing together a puzzling case of autoimmunity, rheumatologists are tasked with understanding how systems fundamentally work. In fact, this emphasis on systems-based thinking is often what draws and keeps the best and smartest physicians within…
State by State—an Update on Proposed Legislation to Benefit Rheumatology
The state legislative tracker shows rheumatology-related bills the ACR is actively tracking in state legislatures across the country. It lists bills by issue area and state and is regularly updated to show each bill’s progression through the legislative process.
Advocate from Home for Medicare Payment Reform on Capitol Hill
As ACR leaders and volunteers visit Capitol Hill to advocate for stabilizing Medicare physician payment rates, you can join the effort from anywhere. Send your lawmakers a message today through the Legislative Action Center.
An Inside Look at the Advocacy Leadership Conference
At this year’s Hill Day, attendees will receive in-depth training on Medicare reimbursement and hear from Rep. Larry Bucshon, MD, (R-Ind.) about his perspective on the issue as a physician in Congress.
Advocacy Leadership Conference to Support Inflation-Linked Medicare Payment Increases
On May 7, ACR leaders from the Board of Directors, committees and more will to go to Capitol Hill and ask lawmakers to support legislation that would stabilize Medicare reimbursement for physicians.
CMS Updates the Medicare Conversion Factor
The Consolidated Appropriations Act, 2024 increased the Medicare conversion factor by 1.68% effective March 9, bringing it to $33.2875 for March 9–Dec. 31, 2024.
UnitedHealthcare Updates Reimbursement for Infliximab Biosimilars
On April 1, UnitedHealthcare updated reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
FDA Proposal for Biosimilar Use in 2025 Budget
A proposal for biosimilar use in the 2025 budget would allow substitution of any biosimilar for its reference product without an interchangeable designation. The hope is to increase biosimilar uptake, with the subsequent potential to increase product “competition, access and affordability.”1 In the 2025 budget proposal, the Biden administration noted that the legal distinction between…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 94
- Next Page »